奥比努图库单抗
滤泡性淋巴瘤
医学
美罗华
肿瘤科
化疗
淋巴瘤
内科学
单克隆抗体
CD20
免疫学
抗体
作者
Robert Marcus,Andrew Davies,Kiyoshi Ando,Wolfram Klapper,Stephen Opat,Carolyn Owen,Elizabeth H Phillips,Randeep Sangha,Rudolf Schlag,John F. Seymour,William Townsend,Marek Trněný,Michael Wenger,Günter Fingerle‐Rowson,Kaspar Rufibach,Tom Moore,Michael Herold,Wolfgang Hiddemann
标识
DOI:10.1056/nejmoa1614598
摘要
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI